胸腺肽α1治疗老年慢性阻塞性肺病急性发作期的疗效观察  

The curative effect of the thymosin alpha 1 in elderly chronic obstructive pulmonary disease during acute period

作　　者：陈海英[1] 张键[1] 

机构地区：[1]湖南省常德市第一人民医院老年病科,415000

出　　处：《中国现代医药杂志》2012年第6期14-16,共3页Modern Medicine Journal of China

摘　　要：目的探讨胸腺肽α1治疗老年慢性阻塞性肺病(COPD)急性发作期的疗效。方法将54例老年COPD急性期住院患者随机分为常规治疗组和胸腺肽治疗组2组,胸腺肽治疗组在常规治疗组基础上加用胸腺肽α11.6mg皮下注射,1次/d,疗程2周。观察2组患者血清C反应蛋白(CRP)和降钙素原(PCT)水平、细胞免疫功能水平和临床疗效。结果治疗后胸腺肽组CD3+、CD4+、CD4+/CD8+水平较常规组明显改善(P<0.05),CRP和PCT水平较常规组明显下降(P<0.05),临床有效率较常规组明显提高(P<0.05)。结论胸腺肽α1能改善老年COPD患者的免疫功能,联合胸腺肽α1治疗老年COPD急性发作期效果明显。Objective To study the curative effect of the thymosin alpha 1 in elderly chronic obstructive pulmonary dis- ease （COPD） during acute period. Methods 54 elderly inpatients with COPD during acute period were divided into two groups randomly： conventional therapy group and thymosin alpha 1 therapy group. Both two groups were treated with routine method, but the patients of the thymosin alpha 1 therapy group received 1.6mg thymosin alpha 1 through subcutaneous injection qd for 2 weeks, to observe serum C-reactive protein （CRP） and procaleitonin （PCT）,cellular immune function and therapeutic effect. Results CD3＋,CD4＋,CD4＋/CD8＋ of the thymosin alpha 1 therapy group were improved significantly and better than conventional therapy group （P〈0.05） ,CRP and PCT were obviously decreased （P〈0.05）, the clinical effective rate was higher （P〈0.05）. Conclusion Thymosin alpha 1 is of great benefit to immune function of elderly COPD patients. The therapeutic effect of combination with thymosin alpha 1 therapy in elderly COPD patients during acute period is obvious.

关 键 词：胸腺肽Α1 慢性阻塞性肺病老年 

分 类 号：R563.9[医药卫生—呼吸系统]